Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde, Revue du Rhumatisme, vol.81, issue.4, pp.303-312, 2014. ,
Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis, The Journal of Clinical Pharmacology, vol.48, issue.6, pp.681-695, 2008. ,
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum. juin, vol.46, issue.6, pp.1451-1460, 2002. ,
Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis, Clinical Pharmacokinetics, vol.54, issue.11, pp.1107-1123, 2015. ,
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ? inhibitor infliximab, Arthritis & Rheumatism, vol.54, issue.12, pp.3782-3789, 2006. ,
Monitoring Drug and Antidrug Levels: A Rational Approach in Rheumatoid Arthritis Patients Treated with Biologic Agents Who Experience Inadequate Response While Being on a Stable Biologic Treatment, BioMed Research International, vol.2014, pp.1-8, 2014. ,
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.64, issue.5, pp.704-707, 2005. ,
Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis, Scandinavian Journal of Rheumatology, vol.47, issue.5, pp.345-350, 2018. ,
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial, Gut, vol.63, issue.11, pp.1721-1727, 2014. ,
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis, British Journal of Clinical Pharmacology, vol.78, issue.1, pp.118-128, 2014. ,
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions, Frontiers in Medicine, vol.2, 2015. ,
Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study, Therapeutic Drug Monitoring, vol.33, issue.4, pp.411-416, 2011. ,
Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study, Arthritis & Rheumatism, vol.61, issue.5, pp.569-576, 2009. ,
Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission, Clinics and Research in Hepatology and Gastroenterology, vol.40, issue.1, pp.90-98, 2016. ,
Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De?Escalation in Adults With Inflammatory Bowel Diseases, Clinical Pharmacology & Therapeutics, vol.106, issue.3, pp.605-615, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02086789
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease, Gastroenterology, vol.148, issue.7, pp.1320-1329.e3, 2015. ,
The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis, British Journal of Clinical Pharmacology, vol.76, issue.6, pp.939-945, 2013. ,
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis, The Lancet, vol.385, p.S48, 2015. ,
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1233-1238, 2007. ,
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn?s Disease, Gastroenterology, vol.154, issue.5, pp.1343-1351.e1, 2018. ,
Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis, Arthritis & Rheumatology, vol.69, issue.1, pp.108-113, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01980809
Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects, Annals of the Rheumatic Diseases, vol.74, issue.2, pp.361-368, 2013. ,
Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review, Journal of Gastroenterology, vol.52, issue.1, pp.19-25, 2016. ,
How to dose infliximab in rheumatoid arthritis: new data on a serious issue, Annals of the Rheumatic Diseases, vol.68, issue.8, pp.1237-1239, 2009. ,
Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers, Biologics: Targets and Therapy, p.67, 2016. ,
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab, Clinical Gastroenterology and Hepatology, vol.11, issue.6, pp.654-666, 2013. ,
Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab, Journal of Market Access & Health Policy, vol.3, issue.1, p.29229, 2015. ,
Critères de réponse dans les spondylarthropathies : définition d'un répondeur, Rev Rhum Monogr. févr, vol.77, issue.1, pp.52-60, 2010. ,
Évaluation de l?activité de la polyarthrite rhumatoïde, Revue du Rhumatisme Monographies, vol.84, issue.4, pp.343-346, 2017. ,
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis, Arthritis Research & Therapy, vol.11, issue.6, p.R178, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00375858
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept, Annals of the Rheumatic Diseases, vol.70, issue.2, pp.284-288, 2010. ,
Key findings towards optimising adalimumab treatment: the concentration?effect curve, Annals of the Rheumatic Diseases, vol.74, issue.3, pp.513-518, 2013. ,
Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab, Mediators of Inflammation, vol.2017, pp.1-7, 2017. ,
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I?III Clinical Trials, Clinical Pharmacokinetics, vol.58, issue.10, pp.1309-1321, 2019. ,
Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Sp, Arthritis Care & Research, vol.63, issue.S11, pp.S47-S58, 2011. ,
Test?retest reliability of the Disease Activity Score 28 CRP (DAS28-CRP), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen joints, Clinical Rheumatology, vol.32, issue.10, pp.1493-1500, 2013. ,